34% of Professional Investors Are Interested in Building Biodiversity-themed Financial Products
Global sustainability tech platform, Clarity AI and impact data and analytics provider GIST Impact recently convened over 180 asset managers, wealth managers, and asset owners for a highly engaging virtual event, to discuss the crucial role of biodiversity in the investment landscape.
The virtual event shed light on the substantial commitment of financial institutions to incorporate biodiversity into their decision-making processes. Notably, the 140 signatories of the Finance for Biodiversity initiative collectively manage an impressive $20 trillion in assets. This signals a noteworthy upcoming shift within the industry; currently investments focused on biodiversity represent only $2.9 billion compared to the over $40 trillion associated with the broader ESG market.
When surveyed during the event, more than two-thirds of participants highlighted "building biodiversity-themed financial products," and "setting company strategy and targets using the TNFD framework" as the most important priorities on biodiversity, with each answer receiving 34% and 33% of the vote respectively.
Angel Agudo, Board Director and SVP of Product at Clarity AI, expressed enthusiasm about the distribution of the 140 signatories among countries in the Finance for Biodiversity initiative. Mr. Agudo highlighted France as a leading nation where this initiative has materialized into specific regulations. However, he also emphasized the positive global representation, including the Netherlands, the UK, the USA, and other regions. Agudo anticipates the continuous growth of global representation, with more individuals joining the cause from diverse geographies.
Mr. Agudo noted, “I believe that science is great for all of us, not only for the economy but also for our survival. The good thing is that we are seeing very positive traction in the market recognizing the importance of biodiversity. We are acknowledging that it deserves attention and creating products that address the challenge, identifying the right companies and policies to improve their impact on this dimension.”
Pavan Sukhdev, the CEO and founder of GIST Impact and former president of WWF International, emphasized the importance of credible biodiversity impact data and how GIST Impact and Clarity AI’s work is meeting that need, revealing that together they are enabling access to extensive data on over 13,000 of companies. This data empowers participants to assess and compare nature-related impacts and dependencies within their specific sectors.
Mr. Sukhdev provided an example for those interested in creating biodiversity-themed products, suggesting that understanding the Potentially Disappearing Fraction (PDF) of species and its changes over time can serve as a valuable initial indicator for creating an index or deciding what to incorporate into an ETF.
On data availability and estimation capabilities, Mr. Sukhdev said, “While companies may not always disclose all the necessary information regarding their emissions, waste, and pollution, our approach allows us to provide estimates and calculate the Potentially Disappearing Fraction (PDF) of species as a measure of biodiversity impact. With this, we can compare impacts, for example, between similar chemical factories in France and across Europe.”
On AI, Mr. Agudo added, “Ensuring the quality of data is crucial, and technology can help with systematic data validation. Using reliability algorithms and models, data points can be challenged and put into context across time, industry benchmarks, and other indicators. Outliers can be easily identified, and engagement with companies can help improve their disclosure and data accuracy. For users managing portfolios composed of multiple companies or funds, technology facilitates data aggregation from asset-level data to portfolio-level data. This automation enables users to manage portfolios effectively and make informed decisions about including or excluding companies based on their impact and risk profiles related to biodiversity.”
Clarity AI recognizes the ongoing efforts and acknowledges the importance of measuring and disclosing corporate impacts on biodiversity. The company remains dedicated to providing tools, data, and methodologies to empower investors to incorporate biodiversity considerations in a meaningful and impactful manner into portfolios, goal-setting and reporting.
About Clarity AI:
Clarity AI is a sustainability technology platform that uses machine learning and big data to deliver environmental and social insights to investors, organizations, and consumers. Clarity AI’s capabilities are an essential tool for end-to-end sustainability analysis related to investing, corporate research, benchmarking, consumer ecommerce, and regulatory reporting. As of June 2023, Clarity AI’s platform analyzes more than 70,000 companies, 420,000 funds, 201 countries, and 199 local governments, which represents more breadth than any other player in the market. One way Clarity AI delivers on its mission to bring societal impact to markets is by ensuring its capabilities are delivered directly into clients' workflows through integrations with partners like BlackRock - Aladdin, Refinitiv an LSEG business, BNP Manaos, CACEIS, and Simcorp. Additionally, Clarity AI's sustainability insights reach more than 150 million consumers across more than 400,000 merchants on the Klarna platform. Clarity AI has offices in North America, Europe, and the Middle East, and its client network manages tens of trillions in assets and includes companies like Invesco, Nordea, BlackRock, Santander, Wellington, and BNP Paribas.
About GIST Impact
GIST Impact is a leading impact data and analytics provider that has been measuring and quantifying corporate impacts for more than 15 years.
GIST Impact’s historic and deep expertise in the economics of ecosystems and biodiversity (TEEB) enriches its clients' knowledge of their impacts and dependencies on nature.
With a team of 100+ scientists, engineers, data scientists and ecological and environmental economists, GIST Impact codifies this experience within its market-leading impact platforms and datasets, covering 12,800+ companies with geographically precise, time-series data.
GIST Impact works with pioneering companies across all sectors and with investors representing over $8 trillion in assets under management.
GIST Impact also partners with some of the world's largest ESG data providers, business networks, and fintech platforms to enable impact measurement across global markets.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230719446459/en/
Contact information
Clarity AI Media Contact
Edelman Smithfield
clarityai@edelmansmithfield.com
GIST Impact Media Contact
Alexandra Downs
alexandra@gistimpact.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 14:00:00 EET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed. “This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 12:08:00 EET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 11:44:00 EET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 11:00:00 EET | Press release
Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE. “Insurance is an industry where the stakes of using AI are particularly high: the decisions can affect millions of people. Allianz and Anthropic both take that very seriously, and we look forward to working together to make insurance better for those w
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 08:00:00 EET | Press release
MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind, placebo-controlled study designed to confirm the promising efficacy signals and favorable safety profile previously observed in MH002’s Phase 2a studies. MH002, a rationally designed live microbial consortium, is the most advanced Live Biotherapeutic Product (LBP) of its kind, targeting disease-specific mechanisms through a synergistic combination of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
